The shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded with a loss of -0.18 points or -0.34% in the most recent session. The shares last traded at $52.03. As per the trading info, the shares saw $51.93 million in upticks and lost $30.08 million in downticks, resulting in a net money flow of $21.85 million. The up/down ratio for the day was measured at 1.73. For the week, the shares had posted -1.85%.From the block trade data available, the total upticks were valued at $33.17 million and the total downticks were valued at $9.22 million, thereby putting the up/down ratio at 3.6. The net money flow for the block transaction was $23.95 million.
Teva Pharmaceutical Industries Limited has dropped 1.89% in the last five trading days, however, the shares have posted positive gains of 0.55% in the last 4 weeks. Teva Pharmaceutical Industries Limited has dropped 3.19% during the last 3-month period . Year-to-Date the stock performance stands at -19.76%.
Currently the company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 64.03% of Teva Pharmaceutical Industries Limited shares. .
Teva Pharmaceutical Industries Limited (NYSE:TEVA) witnessed a decline in the market cap on Friday as its shares dropped 0.38% or 0.2 points. After the session commenced at $52.03, the stock reached the higher end at $52.5 while it hit a low of $51.6. With the volume soaring to 3,758,816 shares, the last trade was called at $52.01. The company has a 52-week high of $72.31. The company has a market cap of $47,537 million and there are 914,000,000 shares in outstanding. The 52-week low of the share price is $49.51.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.